By Fineline Cube 
Keymed Biosciences Inc. (HKG: 2162) announced that it has entered into an exclusive licensing agreement with multinational pharmaceutical company Aeira Pte. Ltd. for the marketing registration and commercialization of Stapokibart injection (trade name: Kangyueda; R&D codename: CM310) across 18 countries and regions in Southeast Asia and Central Asia. The deal — with upfront and milestone payments plus royalties of up to a high double‑digit percentage — extends the global footprint of China’s approved IL‑4Rα antibody beyond its home market.
Deal Terms at a Glance
| Item | Detail |
|---|---|
| Parties | Keymed Biosciences (HKG: 2162) and Aeira Pte. Ltd. |
| Structure | Exclusive licensing agreement |
| Asset | Stapokibart injection (Kangyueda / CM310) |
| Licensed Territory | 18 countries and regions across Southeast Asia and Central Asia |
| Upfront Payment | To be received by Keymed (amount undisclosed) |
| Milestones | Approval milestones per country plus commercialization milestone payments |
| Royalties | Up to a high double‑digit percentage of net sales in the licensed territory |
| Manufacturing | Keymed retains responsibility for manufacture and product supply to Aeira |
Licensed Territory Breakdown
| Region | Countries / Regions |
|---|---|
| Southeast Asia (11) | Brunei Darussalam, Cambodia, Indonesia, Lao PDR, Malaysia, Myanmar, the Philippines, Singapore, Thailand, Timor‑Leste, Vietnam |
| Central Asia (5) | Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan |
| Greater China Adjacent (2) | China’s Hong Kong SAR, Macao SAR |
Aeira will lead registration filings and commercialization across all 18 markets, while Keymed Biosciences maintains manufacturing and supply control — preserving quality assurance and a durable supply revenue stream.
Drug Profile & Approved Indications
- Molecule: Stapokibart, a high‑efficient, humanized antibody targeting the interleukin‑4 receptor alpha subunit (IL‑4Rα)
- Clinical Profile: Demonstrated good safety and encouraging efficacy across multiple previous clinical trials
- China Approval History:
| Indication | China Approval Date |
|---|---|
| Moderate‑to‑severe atopic dermatitis in adults | September 2024 |
| Chronic rhinosinusitis with nasal polyposis | December 2024 |
| Seasonal allergic rhinitis | February 2025 |
Market Impact & Outlook
- Multi‑market scale: Coverage of 18 countries and regions across Southeast and Central Asia — plus Hong Kong and Macao — gives Stapokibart one of the broader regional licensing footprints for a China‑originated immunology antibody
- Royalty quality: Royalties of up to a high double‑digit percentage on net sales represent strong economics for Keymed Biosciences, reinforced by manufacturing and supply responsibilities
- Proven asset: With three approved indications in China and a solid safety and efficacy record, Stapokibart enters new markets as a clinically validated IL‑4Rα competitor rather than a development‑stage risk
- Regional partner fit: Aeira’s multinational infrastructure positions it to navigate the diverse regulatory landscapes of Southeast and Central Asia, where atopic dermatitis and allergic disease prevalence continue to rise
Forward‑Looking Statements — This brief contains forward‑looking statements regarding registration filings, approval timelines, commercialization, and royalty realization for Stapokibart in the licensed territory. Actual results may differ materially due to regulatory, competitive, manufacturing, and market risks. No investment decision should be made solely on the basis of this brief.-Fineline Info & Tech